Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don’t see how podiatry is relevant lol
For legal purposes, please be clear about exactly what type of manipulation you are accusing the authors of- thank you.
I agree. I like the experts where I can see their CVs. I like them even more if they have relevant degrees to what they are opining on!
The right side has no Medical Doctorates Designations, I'd be worried following that group.
yes that is one way, but not the way nwbo is doing it
Data Manipulation Meaning: Manipulation of data is the process of manipulating or changing information to make it more organized and readable.
add in nwbo as well (without data manipulation) LOL
add in nwbo as well (without data manipulation) LOL
I never thought of it that way, but if LP was looking to keep the Institutions out until the company was ready to really have explosive growth, the way to do it is by keeping the share price below where they can take an interest. Certainly she hurt those who bought years ago and didn't average down, but for those who averaged down, perhaps still over $1, this could still be the best opportunity of their lives.
If the company isn't bought out in the next year, and if it's selling at $5 or more you can bet that Institutions will own well over half of it. Certainly some of these shares will be newly issued, but the majority will come from many of us. We will make the greatest percentage gains, but they will make the greatest dollar gains.
Gary
"experts" LOL that is funny
Pretty much 100% failure in the last 3 decades for nGBM/rGBM except for NWBO.
Nope that is wrong
the non-experts are all paid to say it was a nonsuccess.
LOL. they would last last longer if they did not fail early 99% of the time.
Agreed. GBM trials take longer than 15 years when going for the gold standard endpoint, 5 year OS
LOL I am just correcting a serious misunderstanding, clinical trials in GBM do not take 15 years on average
Yeah, and 99.9% of trials don't get 5 year OS data. This takes even longer.
...and many funds/institutions don't invest in OTC... so will have to wait for the uplist.
actually ytd is down about 7% but YR/YR is down 43%. I would call that crushed
LOL it is 15 years for total development, NOT clinical trials LOL sheeze
We have not been crushed YTD. We’ve been flat for the YTD measure, and in fact the other pre-revenue companies I follow are now coming back.
jammy32,
Who says they aren’t following? The bigs won’t publicize until they have their position and right now they can’t get in due to self imposed restrictions designed to mitigate risk for their clients. Timing is everything for them too as big pharma has been good for producing good returns for them so cutting them off to move in a different or more restricted direction will only come at the officially derisked time. Current longs have had no such restrictions placed on them but in this case the “risk” of not following others is in the depth of one’s own due diligence (confidence factor) and ability to wait (time and opportunity cost). Those who run out of confidence or time sell. Those who wait find ways to do so even if needing to complain about waiting to release some frustration. A more constructive approach might be to write to a representative about how “the process” is affecting patients which might be them or someone they love someday. Best wishes.
An expert said it. LOL LOW(Laughing Out Wildly)
It's acts ok. Nothing to write home about.
it has already been shared numerous times
Dr. Anna Barker saying pharma takes 15 years and $2 Billion dollars to get to market. That's for Big Pharma, let alone the 'lil $NWBO. We are Right On Time and budget !! Video Sept. 2022. #DCVAX #NWBO pic.twitter.com/RsKB99fAw9
— LearningEveryTrade 🚀📈💰 (@EveryTrade) September 28, 2022
Proof that average trial is 15 years
yeah, the market is crushing everyone except nwbo who is flat YTD
Adding a little this morning. Can’t see them keeping the SP this low much longer. JMHO
Stock market is crushing pre-revenue companies. I no longer think we see 4-8 bucks on approvals.
Certainly t/o are more likely with approvals.
667% premium is not uncommon. See AZN what they did.
Scotty what is the basis that you “think” the market is looking for NWBO revenue. That seems very doubtful imo
I'm up 63% on a large position from 2016. Up 253% on another large stake from 2020. If that's failure give me more.
ILT
LOW. LOL. This is not an elite pharmaceutical company, it is a clinical stage biotech. Things take time, yes, we have surpassed the 15 year average for a new drug to be developed. Rest assured, market cap is keeping up with dilution just fine, so the 70 cents might be deceiving.
667% premium is not uncommon. See AZN what they did.
https://endpts.com/astrazeneca-nabs-a-small-rare-disease-gene-therapy-player-for-667-premium/
I think the market now wants revenues, not just approvals.
Shares might jump if market is expecting 3 million in 2023 q4 revenue and its 5 million.
Tough to say. There is no denying shares are 70 cents!!!
No, it is actually 2022. The year NWBO got PIP approval. The year NWBO is likely to get commercial manufacturing certification. The year NWBO is likely to submit their MAA (and maybe BLA).
Have a great one Jammy!
OTC isn't my idea of a full fledged market.
market is down nearly 30%. nwbo is flat. nGBM survival more than doubled. We saw survival numbers that have never been seen before with rGBM. The data is great and the stock is holding its' own. Keep in mind nwbo is still in a quiet period and hasn't even started PR. Things are looking good scotty!
LOL. Now it’s 2024. Then it will be 2026. Then it will be 30 years. Wake up. It’s 70 cents for a reason. It’s what the market wants
Hoffman the market has shifted on valuing nwbo since "tld" and the lower then expected 5 yr data.
Guessing approvals (depending on individual approval) 2-3 bucks a share; market will now value nwbo on revenue which will be 2023-2024 (begin) or a takeover.
It's not me saying this it's the market.
can't wait for your end of year $15 target price!
(rounded)
average trial is 15 years. This trial is the only gbm trial to get 5 year survival data. approvals are coming and the world will know about it once nwbo exits the quiet period and starts their pr push
Dilutions. Linda powers -95% since ceo?
This is how I see the next few months going...
Yeah but still 70 cents a share no matter how much BA is posted. If this was a winner, shareholders would be winning.
What’s it been , 20 years of waiting. Wow
LOLOLOL, a buyer of 10s of millions of shares has done a ton to support the stock. I could see a short argument that he hasn't done anything to support their positions, but for longs, his investment is big!
have a great one jammy!
This post ‘ Hugh Guy has done nothing for the stock.
Followers
|
1629
|
Posters
|
|
Posts (Today)
|
34
|
Posts (Total)
|
705013
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |